Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients – Knowledge from two independent international studies
-
Published:2023-03
Issue:
Volume:37
Page:100877
-
ISSN:1476-5586
-
Container-title:Neoplasia
-
language:en
-
Short-container-title:Neoplasia
Author:
Zhou Jian-GuoORCID,
Liang Rui,
Wang Hai-Tao,
Jin Su-Han,
Hu Wei,
Frey Benjamin,
Fietkau Rainer,
Hecht Markus,
Ma Hu,
Gaipl Udo S.
Reference54 articles.
1. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma;Amaria;Nat. Med.,2018
2. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N. Engl. J. Med.,2015
3. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial;Ascierto;Lancet Oncol.,2020
4. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer;André;N. Engl. J. Med.,2020
5. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study;Overman;Lancet Oncol.,2017
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献